Search results
Author(s):
Charles L Campbell
,
Eric J Topol
,
Steven R Steinhubl
Added:
3 years ago
The complications of atherosclerotic disease comprise the primary cause of mortality in the world today. Acute complications such as sudden cardiac death, myocardial infarction and stroke are typically due to the formation of a intra-arterial thrombus at the site of a rupture or erosion of an atherosclerotic lesion, with platelet activation and aggregation central to thrombus formation. Aspirin,…
View more
Author(s):
Mandeep Mehra
,
Christian Inchaustegui
Added:
4 months ago
AHA 2023 - Investigator, Dr Mandeep Mehra (Brigham and Women's Hospital, US) is interviewed by Dr Christian Inchaustegui (Oregon Health & Science University, US), CardioNerds Ambassador, on the findings of the ARIES HM3 trial (NCT04069156).ARIES HM3 is a prospective, randomised, double-blinded, placebo-controlled clinical investigation into heart failure (HF) patients treated with the ARIES…
View more
Author(s):
Masahiro Natsuaki
Added:
7 months ago
ESC 23 — Dr Masahiro Natsuaki (Saga University, JP) discusses the short and optimal duration of dual antiplatelet therapy-3 Study (STOPDAPT-3) (NCT04609111).
In the STOPDAPT-2 study, 1-month dual antiplatelet therapy (DAPT) followed by clopidogrel monotherapy was shown to provide benefits in bleeding reduction over a 12-month period, however, other trials have shown high rates of bleeding at…
View more
Author(s):
Naima Maqsood
,
Jeff Healey
Added:
4 months ago
AHA 2023 — Dr Naima Maqsood, CardioNerds ambassador (Temple University Hospital, US) interviews investigator, Dr Jeff Healey (McMaster University, CA) to outline the findings from a phase 4 trial of apixaban to reduce thromboembolism in patients with subclinical atrial fibrillation (AF).ARTESiA (NCT01938248) aims to determine if apixaban in combination with aspirin can reduce the instance of…
View more
Author(s):
Randall S Stafford
,
Veronica Monti
,
Jun Ma
Added:
3 years ago
Cardiovascular disease (CVD), including myocardial infarction and stroke, is the leading cause of morbidity and mortality in the US. A broad array of randomized trials have demonstrated the benefits of low doses of aspirin (75-325mg)1,2 for both the primary3-7 and secondary8-11 prevention of CVD. Most trials demonstrate a 15-40% reduction in cardiovascular events with chronic aspirin use.Aspirin…
View more
Aspirin and Statins to Decrease Risks of Cardiovascular Disease — The Need for Wider Utilization
Author(s):
Charles H Hennekens
,
Danielle Hollar
Added:
3 years ago
Article
Aspirin and Statins to Decrease Risks of Cardiovascular Disease – The Need for Wider Utilization
Author(s):
Charles H Hennekens
,
Danielle Hollar
,
Arthur S Agatston
Added:
3 years ago
Article
Author(s):
Michelle Goonasekera
Added:
1 year ago
ESC 22 - In this short interview, Dr Michelle Goonasekera (University of Oxford, Oxford, UK) joins us on-site at the ESC congress to discuss the findings of the ASCEND Study(NCT00135226).
ASCEND aimed to evaluate the effects of 100mg daily aspirin on top of 1 gram of omega-3 fatty acids in the prevention of serious vascular events, including non-fatal heart attack, stroke and transient ischaemic…
View more
Author(s):
Randall S Stafford
,
Veronica Monti
,
Jun Ma
Added:
3 years ago
Cardiovascular disease (CVD), including myocardial infarction and stroke, is the leading cause of morbidity and mortality in the US. A broad array of randomized trials have demonstrated the benefits of low doses of aspirin (75-325mg)1,2 for both the primary3-7 and secondary8-11 prevention of CVD. Most trials demonstrate a 15-40% reduction in cardiovascular events with chronic aspirin use.Aspirin…
View more
Author(s):
Johny Nicolas
,
Usman Baber
,
Roxana Mehran
Added:
3 years ago
Seminal clinical trials conducted in the balloon angioplasty and bare metal stent era established the superiority of dual antiplatelet therapy (DAPT) as compared with aspirin monotherapy or anticoagulation with respect to the prevention of thrombotic events.1,2 Other studies found that the benefits of DAPT are durable for at least 1 year and extend to patients with acute coronary syndromes.3–5…
View more